Agilent Technologies acquires Lasergen

Agilent Technologies acquired Lasergen for approximately $185 million (two steps), a transaction completed in May 2018, structured as cash (step-up from a prior minority stake).

Lasergen operates in Diagnostics and Genomics, is based in Houston, Texas, USA. Houston-based Lasergen develops next-generation sequencing chemistry, including its Lightning Terminators technology aimed at making DNA sequencing faster, more accurate and less expensive. Agilent first took a 48% minority stake in March 2016 and acquired the remaining shares in May 2018.

Full ownership of Lasergen gave Agilent the sequencing chemistry to build a complete, integrated clinical next-generation-sequencing workflow and deepen its diagnostics presence.

We are pleased to complete our acquisition of Lasergen.Sam Raha, President, Agilent Diagnostics and Genomics Group

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.